Median Technologies: directors' dealings · France · AMF

About Median Technologies

Median Technologies is a French healthcare technology company listed on Euronext Growth Paris under ticker ALMDT, ISIN FR0011049824. Founded in 2002 by Fredrik Brag, the company was built around advanced expertise in medical imaging, artificial intelligence and image analysis for oncology. Its market position is that of a medtech/healthtech specialist focused on high-value software and services that help improve early cancer diagnosis and accelerate the development of new treatments. In its recent communications, Median describes itself as a developer of AI-powered medical software for early cancer detection and as a globally leading provider of central imaging services and image analyses for oncology drug developers. The company is also eligible for France’s PEA-PME scheme, which highlights its mid-cap profile and growth-oriented positioning. Median Technologies’ business is organized around two main pillars. The first is iCRO, an imaging services activity for oncology clinical trials. Through this unit, the company supports biopharmaceutical partners in the design, monitoring and analysis of clinical studies, providing central image reading, data management and advanced imaging analytics. The second pillar is eyonis™, a suite of software as a medical device (SaMD) powered by AI and designed for early cancer detection, with a particular focus on lung cancer screening. This dual model gives Median a combination of recurring services revenue and longer-term software upside, with the potential for improved margins as the SaaS/SaMD platform scales. The company occupies a strategic niche at the intersection of medical imaging, AI and oncology. It targets major unmet medical needs by offering tools that can improve diagnostic accuracy and shorten the timeline for oncology drug development. Its customer base includes large international pharmaceutical companies involved in cancer clinical trials. Median has an international footprint, with commercial and operational activities serving Europe, North America and other major clinical research markets, supported by an organization designed for multi-country programs. Notable features of the company include its proprietary capabilities in computer vision, signal processing and AI applied to medical imaging, as well as its ongoing clinical and regulatory progress around eyonis™.